A 34-year-old woman with bipolar affective disorder type I has been stable on lithium carbonate 1000mg daily for 4 years. She develops recurrent urinary tract infections and her GP requests blood tests. Results show: lithium level 0.8 mmol/L, creatinine 145 μmol/L (baseline 85 μmol/L), eGFR 42 ml/min/1.73m² (baseline 88). She is otherwise well with no oedema. What is the most appropriate next step in managing her bipolar disorder?
Q82
What is the minimum duration of symptoms required to diagnose schizophrenia according to ICD-11 criteria?
Q83
A 32-year-old man with a 2-year history of schizophrenia presents with increasingly disorganised behaviour and poor self-care. He has been non-adherent with oral risperidone. His care coordinator reports he forgets to take medication and lacks insight into his illness. He has had three hospital admissions in the past year. He agrees he needs treatment but finds it difficult to remember tablets. What is the most appropriate pharmacological intervention?
Q84
A 50-year-old man with a 22-year history of paranoid schizophrenia has been on clozapine 550mg daily for 8 years. He attends A&E with a 4-day history of increasing confusion, fever, and reduced mobility. Examination shows temperature 38.9°C, pulse 115 bpm, blood pressure 170/105 mmHg, marked muscle rigidity, profuse sweating, and fluctuating consciousness (GCS 13/15). Blood tests show: WBC 15.2 × 10⁹/L, neutrophils 12.1 × 10⁹/L, CK 8500 U/L, creatinine 156 µmol/L. What is the most likely diagnosis and immediate management priority?
Q85
A 27-year-old man diagnosed with paranoid schizophrenia 14 months ago has been treated with olanzapine 20mg daily with good control of positive symptoms. He now presents with concerns about weight gain (BMI increased from 24 to 31 kg/m²), excessive daytime sleepiness, and loss of libido. Fasting blood tests show: glucose 6.8 mmol/L, HbA1c 44 mmol/mol, total cholesterol 6.2 mmol/L, triglycerides 3.8 mmol/L, prolactin 420 mU/L (normal). He is worried about these side effects but anxious about changing medication. What is the most appropriate management?
Q86
A 46-year-old man with bipolar affective disorder type I is admitted with acute mania (YMRS score 38). He is aggressive, refusing oral medication, and requires restraint. He has no known allergies. Physical examination shows pulse 118 bpm, blood pressure 165/95 mmHg, temperature 37.4°C. He has no cardiovascular history and ECG shows sinus tachycardia only. What is the most appropriate initial pharmacological intervention?
Q87
A 33-year-old woman with paranoid schizophrenia has been taking amisulpride 800mg daily for 18 months with partial improvement in positive symptoms but persistent negative symptoms including social withdrawal, lack of motivation, and blunted affect. She reports feeling 'emotionally flat' and unable to experience pleasure. Physical examination and blood tests including prolactin are normal. She is concerned about her quality of life. What is the most appropriate management to address her negative symptoms?
Q88
What is the recommended frequency of lithium level monitoring in a patient who has been stable on lithium therapy for more than 2 years with consistent results?
Q89
A 55-year-old man with chronic paranoid schizophrenia has been on clozapine 600mg daily for 5 years with good symptom control. He presents to A&E with a 2-day history of severe constipation, abdominal distension, and vomiting. Examination shows temperature 37.8°C, pulse 105 bpm, blood pressure 110/70 mmHg, abdomen markedly distended with absent bowel sounds. Abdominal X-ray shows dilated bowel loops with maximum caecal diameter of 11cm. Blood tests show WBC 11.2 × 10⁹/L, neutrophils 8.5 × 10⁹/L, CRP 45 mg/L. What is the most important immediate management step?
Q90
A 42-year-old woman with bipolar affective disorder type II has experienced eight depressive episodes in the past 2 years despite treatment with lithium carbonate 800mg daily (level 0.7 mmol/L). She has had only two brief hypomanic episodes in the same period. She reports the depressive episodes are severely impacting her ability to work and maintain relationships. Physical examination and routine blood tests are normal. What is the most appropriate medication adjustment?
Severe Mental Illness UK Medical PG Practice Questions and MCQs
Question 81: A 34-year-old woman with bipolar affective disorder type I has been stable on lithium carbonate 1000mg daily for 4 years. She develops recurrent urinary tract infections and her GP requests blood tests. Results show: lithium level 0.8 mmol/L, creatinine 145 μmol/L (baseline 85 μmol/L), eGFR 42 ml/min/1.73m² (baseline 88). She is otherwise well with no oedema. What is the most appropriate next step in managing her bipolar disorder?
A. Continue lithium and monitor renal function closely
B. Reduce lithium dose and recheck levels
C. Stop lithium and switch to sodium valproate (Correct Answer)
D. Stop lithium and switch to lamotrigine
E. Add amiloride to protect renal function
Explanation: ***Stop lithium and switch to sodium valproate***
- The patient has developed significant **chronic kidney disease (CKD)** with eGFR falling from 88 to **42 ml/min/1.73m²**; guidelines recommend stopping lithium when eGFR is consistently below **45 ml/min/1.73m²**.
- **Sodium valproate** is a first-line alternative for maintenance therapy in **Bipolar I disorder** to prevent mania and is not cleared renally, making it safer in this context.
*Continue lithium and monitor renal function closely*
- Continuing lithium despite a significant and sustained drop in **eGFR** risks progression to end-stage renal failure and increases the risk of **lithium toxicity** due to reduced clearance.
- Monitoring alone is insufficient when the eGFR has already halved and is below the recommended threshold for **discontinuation**.
*Reduce lithium dose and recheck levels*
- While dose reduction lowers current serum levels, it does not stop the underlying **lithium-induced interstitial nephritis** which is likely driving the renal decline.
- Guidelines emphasize that persistent renal impairment at this level requires an **alternative mood stabilizer** rather than just dosage adjustment.
*Stop lithium and switch to lamotrigine*
- **Lamotrigine** is primarily effective for preventing **bipolar depression** and is generally not the first choice for preventing mania in **Bipolar I disorder**.
- Although it is safer for the kidneys, **sodium valproate** or an antipsychotic is usually preferred for stabilizing patients with a history of significant manic episodes.
*Add amiloride to protect renal function*
- **Amiloride** is specifically used to treat **lithium-induced nephrogenic diabetes insipidus** (polyuria) by blocking epithelial sodium channels in the collecting duct.
- It does not reverse or prevent the decline in **glomerular filtration rate (GFR)** associated with chronic lithium-induced kidney disease.
Question 82: What is the minimum duration of symptoms required to diagnose schizophrenia according to ICD-11 criteria?
A. 2 weeks
B. 1 month (Correct Answer)
C. 3 months
D. 6 months
E. 1 year
Explanation: ***1 month***
- This is the minimum duration of **core clinical features** required for a diagnosis of schizophrenia according to **ICD-11 criteria**.
- These features include **delusions, hallucinations, disorganized thinking, or negative symptoms** that cause significant impairment, present for most of the time during this period.
*2 weeks*
- A duration of **2 weeks** is typically too short for a diagnosis of schizophrenia and is more consistent with an **Acute and Transient Psychotic Disorder**.
- Schizophrenia requires a more sustained pattern of symptoms to differentiate it from brief, self-limiting psychotic episodes.
*3 months*
- While schizophrenic symptoms often persist for this duration, **3 months** is not the specific minimum diagnostic criterion used by ICD-11.
- This period may represent an **active phase** of the illness but is not the established cutoff for initial diagnosis.
*6 months*
- This duration, including prodromal, active, and residual symptoms, is the diagnostic requirement for **schizophrenia according to DSM-5 criteria**.
- **ICD-11** employs a shorter **1-month** criterion to facilitate earlier diagnosis and clinical intervention.
*1 year*
- A duration of **one year** is significantly longer than the minimum required for an initial diagnosis of schizophrenia by either ICD-11 or DSM-5.
- This timeframe is typically used to describe the **chronicity** or long-term course of the illness rather than its initial diagnostic threshold.
Question 83: A 32-year-old man with a 2-year history of schizophrenia presents with increasingly disorganised behaviour and poor self-care. He has been non-adherent with oral risperidone. His care coordinator reports he forgets to take medication and lacks insight into his illness. He has had three hospital admissions in the past year. He agrees he needs treatment but finds it difficult to remember tablets. What is the most appropriate pharmacological intervention?
A. Commence clozapine
B. Switch to paliperidone palmitate depot injection (Correct Answer)
C. Increase frequency of care coordinator visits to supervise oral medication
D. Commence community treatment order for enforced oral medication
E. Switch to quetiapine as it can be given once daily
Explanation: ***Switch to paliperidone palmitate depot injection***
- A **long-acting injectable (LAI)** antipsychotic is the first-line choice for patients with **non-adherence** to oral medication to prevent relapse and hospital readmission.
- Since the patient has previously tolerated risperidone, **paliperidone palmitate** (the active metabolite of risperidone) is an appropriate choice that ensures consistent therapeutic levels without daily dosing.
*Commence clozapine*
- **Clozapine** is indicated for **treatment-resistant schizophrenia**, defined as failure of at least two different antipsychotics (one being an atypical) at an adequate dose for 6-8 weeks.
- This patient's relapse is clearly linked to **non-adherence** rather than a failure of the medication's therapeutic efficacy itself.
*Increase frequency of care coordinator visits to supervise oral medication*
- While increasing supervision may help temporarily, it is **resource-intensive** and less reliable than the biochemical certainty of a depot injection.
- It does not address the patient's specific struggle with **forgetfulness** as effectively as a long-acting formulation does.
*Commence community treatment order for enforced oral medication*
- A **Community Treatment Order (CTO)** is a legal framework that should only be used if less restrictive options, such as switching to a **depot injection**, have been considered or tried.
- Since the patient **agrees he needs treatment**, a clinical solution to medication delivery is preferred over a legal enforcement of oral tablets.
*Switch to quetiapine as it can be given once daily*
- Switching to another oral medication like **quetiapine** does not solve the underlying issue of **non-adherence** due to forgetfulness.
- Even **once-daily dosing** still requires the patient to remember a specific task every day, whereas a depot injection requires action only once every few weeks or months.
Question 84: A 50-year-old man with a 22-year history of paranoid schizophrenia has been on clozapine 550mg daily for 8 years. He attends A&E with a 4-day history of increasing confusion, fever, and reduced mobility. Examination shows temperature 38.9°C, pulse 115 bpm, blood pressure 170/105 mmHg, marked muscle rigidity, profuse sweating, and fluctuating consciousness (GCS 13/15). Blood tests show: WBC 15.2 × 10⁹/L, neutrophils 12.1 × 10⁹/L, CK 8500 U/L, creatinine 156 µmol/L. What is the most likely diagnosis and immediate management priority?
A. Clozapine-induced agranulocytosis; stop clozapine and start antibiotics
B. Neuroleptic malignant syndrome; stop clozapine and provide supportive care in HDU/ICU (Correct Answer)
C. Serotonin syndrome; stop clozapine and give cyproheptadine
D. Bacterial meningitis; continue clozapine and start ceftriaxone
E. Acute catatonia; continue clozapine and give lorazepam
Explanation: ***Neuroleptic malignant syndrome; stop clozapine and provide supportive care in HDU/ICU***- The patient presents with the classic tetrad of **Neuroleptic Malignant Syndrome (NMS)**: **hyperthermia** (fever 38.9°C), **autonomic instability** (tachycardia, hypertension, profuse sweating), **marked muscle rigidity**, and **altered mental status** (confusion, fluctuating consciousness).- Lab findings of significantly elevated **Creatine Kinase (CK)** (8500 U/L) and **leukocytosis** further confirm NMS, necessitating the immediate withdrawal of the antipsychotic and intensive supportive care in a high-dependency unit or ICU.*Clozapine-induced agranulocytosis; stop clozapine and start antibiotics*- **Agranulocytosis** is characterized by a dangerously low **neutrophil count** (<0.5 x 10⁹/L), but this patient exhibits **neutrophilia** (12.1 × 10⁹/L), making this diagnosis incorrect.- While fever and confusion can occur in agranulocytosis-induced sepsis, they would not be accompanied by profound **lead-pipe muscle rigidity** and massive CK elevation.*Serotonin syndrome; stop clozapine and give cyproheptadine*- **Serotonin syndrome** is typically characterized by **hyperreflexia**, **clonus**, and myoclonus, in contrast to the **"lead-pipe" muscle rigidity** seen in NMS.- It usually results from excessive serotonergic activity, often due to drug interactions involving SSRIs or MAOIs, not primarily from dopamine-blocking agents like clozapine.*Bacterial meningitis; continue clozapine and start ceftriaxone*- While fever and confusion are present, the absence of classic signs like **neck stiffness**, **photophobia**, or a characteristic rash makes meningitis a less likely primary diagnosis.- Meningitis does not explain the **markedly elevated CK** level or the severe autonomic instability and pronounced muscle rigidity observed.*Acute catatonia; continue clozapine and give lorazepam*- **Catatonia** involves motor signs such as stupor, mutism, or waxy flexibility, but it typically lacks the extreme **hyperthermia** and significant **autonomic instability** (e.g., severe sweating, labile blood pressure) seen here.- Continuing clozapine in a patient with suspected NMS is highly dangerous and could lead to worsening of the condition and potential fatal outcomes, whereas NMS necessitates immediate withdrawal of the antipsychotic.
Question 85: A 27-year-old man diagnosed with paranoid schizophrenia 14 months ago has been treated with olanzapine 20mg daily with good control of positive symptoms. He now presents with concerns about weight gain (BMI increased from 24 to 31 kg/m²), excessive daytime sleepiness, and loss of libido. Fasting blood tests show: glucose 6.8 mmol/L, HbA1c 44 mmol/mol, total cholesterol 6.2 mmol/L, triglycerides 3.8 mmol/L, prolactin 420 mU/L (normal). He is worried about these side effects but anxious about changing medication. What is the most appropriate management?
A. Continue olanzapine and add metformin 500mg twice daily
B. Switch to aripiprazole with gradual cross-titration (Correct Answer)
C. Reduce olanzapine to 15mg daily and monitor weight
D. Continue olanzapine and refer to dietician and lifestyle programme
E. Switch to amisulpride 400mg twice daily
Explanation: ***Switch to aripiprazole with gradual cross-titration***
- **Aripiprazole** is a **partial dopamine agonist** known for its favorable **metabolic profile**, making it a good choice for patients experiencing significant weight gain, dyslipidemia, and glucose dysregulation with other antipsychotics.
- A **gradual cross-titration** allows for a smooth transition, minimizing the risk of **withdrawal symptoms** from olanzapine and reducing the chance of **psychotic relapse** as aripiprazole is introduced, while addressing metabolic concerns.
*Continue olanzapine and add metformin 500mg twice daily*
- While **metformin** can help mitigate **weight gain** and improve **insulin sensitivity**, it does not fully address other olanzapine-related side effects such as **excessive daytime sleepiness** or **loss of libido**.
- Continuing the causative agent (olanzapine) fails to resolve the holistic burden of side effects as effectively as a medication switch that targets the root cause.
*Reduce olanzapine to 15mg daily and monitor weight*
- A minor dose reduction from 20mg to 15mg is unlikely to significantly reverse established **metabolic side effects** and **weight gain** (BMI from 24 to 31 kg/m²).
- This approach risks **psychotic relapse** if the lower dose is insufficient, and it does not adequately address the patient's concerns regarding **libido loss** and **sedation**.
*Continue olanzapine and refer to dietician and lifestyle programme*
- While **lifestyle interventions** are recommended, they are often insufficient to counteract the potent **orexigenic effects** and metabolic shifts caused by high-dose olanzapine, especially with established impaired fasting glucose and hypertriglyceridemia.
- This option does not address the **excessive daytime sleepiness** or **loss of libido**, and provides insufficient intervention for significant **cardiovascular risk** factors.
*Switch to amisulpride 400mg twice daily*
- **Amisulpride** is associated with a relatively high risk of **hyperprolactinemia**, which could worsen the patient's existing concern about **loss of libido** and potentially lead to other prolactin-related side effects.
- Although it has a lower metabolic risk than olanzapine, it is not as **metabolically neutral** as aripiprazole, and its **prolactin-elevating potential** makes it less suitable given the patient's current symptoms.
Question 86: A 46-year-old man with bipolar affective disorder type I is admitted with acute mania (YMRS score 38). He is aggressive, refusing oral medication, and requires restraint. He has no known allergies. Physical examination shows pulse 118 bpm, blood pressure 165/95 mmHg, temperature 37.4°C. He has no cardiovascular history and ECG shows sinus tachycardia only. What is the most appropriate initial pharmacological intervention?
A. Intramuscular haloperidol 5mg plus promethazine 50mg (Correct Answer)
B. Intramuscular olanzapine 10mg
C. Intramuscular lorazepam 4mg
D. Oral risperidone 3mg dissolved in water
E. Intramuscular aripiprazole 9.75mg
Explanation: ***Intramuscular haloperidol 5mg plus promethazine 50mg***
- This combination is a first-line recommendation for **rapid tranquilisation** in patients with severe **acute mania** and aggression who refuse oral medication.
- The addition of **promethazine** provides essential sedation and reduces the risk of **extrapyramidal side effects**, particularly acute dystonia, caused by high-potency antipsychotics.
*Intramuscular olanzapine 10mg*
- While effective, **IM olanzapine** carries a significant risk of fatal **cardiorespiratory depression** if administered within an hour of benzodiazepines.
- It is generally avoided in rapid tranquilisation protocols where multiple agents or rescue benzodiazepines might be needed shortly after.
*Intramuscular lorazepam 4mg*
- **Lorazepam** is an alternative for rapid tranquilisation but acts primarily as a sedative without specific **antimanic efficacy**.
- A dose of **4mg IM** exceeds the standard initial recommended dose (usually 1-2mg) for most rapid tranquilisation protocols.
*Oral risperidone 3mg dissolved in water*
- **Oral medication** is inappropriate in this scenario as the patient is actively **aggressive and refusing** oral intake, requiring restraint.
- Rapid tranquilisation protocols must bypass the oral route when a patient presents a high risk of **violence and aggression** and refuses cooperation.
*Intramuscular aripiprazole 9.75mg*
- **IM aripiprazole** has limited evidence and is less commonly used than the haloperidol/promethazine combination for **acute behavioral disturbance** in mania.
- It is generally less effective for achieving the rapid, profound **sedation** required for a patient with a very high YMRS score and physical aggression.
Question 87: A 33-year-old woman with paranoid schizophrenia has been taking amisulpride 800mg daily for 18 months with partial improvement in positive symptoms but persistent negative symptoms including social withdrawal, lack of motivation, and blunted affect. She reports feeling 'emotionally flat' and unable to experience pleasure. Physical examination and blood tests including prolactin are normal. She is concerned about her quality of life. What is the most appropriate management to address her negative symptoms?
A. Increase amisulpride to 1200mg daily
B. Add cognitive behavioural therapy for psychosis (Correct Answer)
C. Switch to aripiprazole monotherapy
D. Add an SSRI antidepressant
E. Add lamotrigine 200mg daily
Explanation: ***Add cognitive behavioural therapy for psychosis***
- **NICE guidelines** recommend offering **CBTp** (Cognitive Behavioural Therapy for psychosis) to all patients with schizophrenia to address both positive and negative symptoms.
- Evidence suggests that psychological interventions are more effective than pharmacological adjustments for improving **negative symptoms** and overall **quality of life** in stable patients.
*Increase amisulpride to 1200mg daily*
- Higher doses of antipsychotics primarily target **D2 receptors** to control positive symptoms and are generally ineffective for **negative symptoms**.
- Exceeding the standard dose (800mg) increases the risk of **extrapyramidal side effects** and secondary negative symptoms due to excessive dopamine blockade.
*Switch to aripiprazole monotherapy*
- While **aripiprazole** has partial agonist properties that might theoretically aid negative symptoms, switching risks **relapse** of the partially controlled positive symptoms.
- The patient's **prolactin** is already normal, so the specific benefit of switching to a 'prolactin-sparing' drug to alleviate emotional flattening is less justified here.
*Add an SSRI antidepressant*
- **SSRIs** are indicated if the patient has a comorbid **depressive episode**, but they are not the primary treatment for core **negative symptoms** of schizophrenia.
- The patient's symptoms (blunted affect, amotivation) are consistent with **primary negative symptoms** rather than secondary depressive features.
*Add lamotrigine 200mg daily*
- **Lamotrigine** is primarily used as a mood stabilizer in **bipolar disorder** or for specific types of epilepsy and is not routinely indicated for schizophrenia.
- There is no strong clinical evidence to support adding lamotrigine to improve **negative symptoms** such as social withdrawal or anhedonia.
Question 88: What is the recommended frequency of lithium level monitoring in a patient who has been stable on lithium therapy for more than 2 years with consistent results?
A. Every 3 months (Correct Answer)
B. Every 6 months
C. Every 12 months
D. Every month
E. Every 2 months
Explanation: ***Every 3 months***
- For patients stable on **lithium therapy** for more than 2 years with consistent levels, the standard monitoring interval is **every 3 months**.
- This frequency is necessary due to lithium's **narrow therapeutic index** and the risk of toxicity from dehydration or drug interactions.
*Every 6 months*
- This interval is typically reserved for monitoring **thyroid function (TSH)** and **renal function (U&Es)** in stable patients.
- Monitoring lithium levels only twice a year is insufficient to ensure safety and detect fluctuations in **serum concentration**.
*Every 12 months*
- Annual monitoring is inappropriate for lithium because it does not allow for timely detection of **nephrotoxicity** or toxic lithium levels.
- Such a long interval significantly increases the risk of unrecognized **lithium toxicity** and long-term side effects.
*Every month*
- Monthly monitoring is primarily indicated during the **titration phase** or when dose adjustments are being made to reach a **steady state**.
- While safe, it is unnecessary and not cost-effective for a patient who has remained **clinically stable** for over two years.
*Every 2 months*
- This frequency is generally used for patients transitioning from titration to stability or those with **borderline renal function**.
- It is more frequent than required by guidelines for patients with a proven history of **consistent therapeutic levels**.
Question 89: A 55-year-old man with chronic paranoid schizophrenia has been on clozapine 600mg daily for 5 years with good symptom control. He presents to A&E with a 2-day history of severe constipation, abdominal distension, and vomiting. Examination shows temperature 37.8°C, pulse 105 bpm, blood pressure 110/70 mmHg, abdomen markedly distended with absent bowel sounds. Abdominal X-ray shows dilated bowel loops with maximum caecal diameter of 11cm. Blood tests show WBC 11.2 × 10⁹/L, neutrophils 8.5 × 10⁹/L, CRP 45 mg/L. What is the most important immediate management step?
A. Stop clozapine and start lactulose
B. Urgent surgical review for possible bowel obstruction (Correct Answer)
C. Continue clozapine and start metoclopramide
D. Stop clozapine and check clozapine level
E. Start broad-spectrum antibiotics and IV fluids
Explanation: ***Urgent surgical review for possible bowel obstruction*** - The patient presents with classic signs of **clozapine-induced gastrointestinal hypomotility (CIGH)**, which has progressed to a severe state of suspected **bowel obstruction** or pseudo-obstruction.- A **caecal diameter of 11cm** (critical threshold >9cm), absent bowel sounds, and systemic signs of inflammation (tachycardia, fever, elevated WBC/CRP) strongly indicate a **surgical emergency** requiring immediate assessment and intervention to prevent **perforation** or **toxic megacolon**.*Stop clozapine and start lactulose* - While stopping clozapine is critical, **lactulose** is an osmotic laxative that can produce gas and worsen **abdominal distension** and pressure in a patient with a potentially complete bowel obstruction.- In acute, severe bowel obstruction, laxatives are contraindicated as they can exacerbate the condition and increase the risk of **perforation**.*Continue clozapine and start metoclopramide* - Continuing clozapine is contraindicated as its potent **anticholinergic effects** are the direct cause of the severe gastrointestinal hypomotility.- **Metoclopramide** (a prokinetic agent) should be avoided in suspected mechanical bowel obstruction as it can increase pressure against the obstruction, potentially leading to **bowel ischemia** or **perforation**.*Stop clozapine and check clozapine level* - While stopping clozapine is appropriate, checking **clozapine levels** is not the most immediate or critical management step in this acute, life-threatening presentation.- The patient's clinical picture is a **surgical emergency** that requires urgent physical assessment and intervention, not a delay for routine lab results.*Start broad-spectrum antibiotics and IV fluids* - **IV fluids** are crucial for supportive care in a distressed patient, but they do not address the primary issue of **bowel obstruction**.- **Broad-spectrum antibiotics** may be indicated later if perforation or sepsis is confirmed, but the immediate priority is identifying and managing the underlying **mechanical/functional obstruction** through surgical assessment.
Question 90: A 42-year-old woman with bipolar affective disorder type II has experienced eight depressive episodes in the past 2 years despite treatment with lithium carbonate 800mg daily (level 0.7 mmol/L). She has had only two brief hypomanic episodes in the same period. She reports the depressive episodes are severely impacting her ability to work and maintain relationships. Physical examination and routine blood tests are normal. What is the most appropriate medication adjustment?
A. Add lamotrigine 25mg daily and titrate to 200mg daily (Correct Answer)
B. Switch lithium to sodium valproate 1000mg daily
C. Add quetiapine 300mg at night
D. Increase lithium to achieve level of 0.9-1.0 mmol/L
E. Add olanzapine 10mg daily
Explanation: ***Add lamotrigine 25mg daily and titrate to 200mg daily*** - **Lamotrigine** is highly effective specifically for preventing **depressive episodes** in patients with **bipolar II disorder**, making it the first-line augmentation choice for this patient's clinical profile. - A slow titration starting at **25mg daily** is mandatory to minimize the risk of serious dermatological adverse effects, such as **Stevens-Johnson syndrome**. *Switch lithium to sodium valproate 1000mg daily* - **Sodium valproate** is generally more effective at preventing **manic** rather than depressive episodes and is less suitable for a patient with frequent depression. - It is generally contraindicated in **women of childbearing potential** due to significant **teratogenic risks**, unless no other options are available. *Add quetiapine 300mg at night* - While **quetiapine** is effective for treating **acute bipolar depression**, it is often less preferred than lamotrigine for long-term **maintenance/prevention** of frequent depressive relapses specifically in bipolar II. - Use is frequently limited by metabolic side effects such as **sedation**, **weight gain**, and glucose dysregulation compared to lamotrigine. *Increase lithium to achieve level of 0.9-1.0 mmol/L* - The patient's lithium level is already within the **therapeutic range (0.6–0.8 mmol/L)** for maintenance, and the clinical issue is a lack of efficacy for prophylaxis, not sub-therapeutic levels. - Increasing to a higher range significantly increases the risk of **lithium toxicity** and chronic renal impairment without guaranteeing better control of depressive symptoms. *Add olanzapine 10mg daily* - **Olanzapine** is primarily utilized for the management of **mania** and preventing manic relapses rather than treating or preventing bipolar depression. - It is associated with significant **metabolic syndrome** risks, including substantial weight gain and lipid abnormalities, which make it less ideal for long-term maintenance.
